122 related articles for article (PubMed ID: 38321024)
21. CircMAN1A2 contributes to nasopharyngeal carcinoma progression via enhancing the ubiquitination of ATMIN through miR-135a-3p/UBR5 axis.
Dang QQ; Li PH; Wang J; Zhao JY; Zhai SN; Zheng YJ; Yang DK
Hum Cell; 2023 Mar; 36(2):657-675. PubMed ID: 36626032
[TBL] [Abstract][Full Text] [Related]
22. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.
Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH
Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689
[TBL] [Abstract][Full Text] [Related]
24. Expression of EIF5A2 associates with poor survival of nasopharyngeal carcinoma patients treated with induction chemotherapy.
Huang PY; Zeng TT; Ban X; Li MQ; Zhang BZ; Zhu YH; Hua WF; Mai HQ; Zhang L; Guan XY; Li Y
BMC Cancer; 2016 Aug; 16(1):669. PubMed ID: 27549330
[TBL] [Abstract][Full Text] [Related]
25. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y
Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364
[TBL] [Abstract][Full Text] [Related]
26. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02).
Frikha M; Auperin A; Tao Y; Elloumi F; Toumi N; Blanchard P; Lang P; Sun S; Racadot S; Thariat J; Alfonsi M; Tuchais C; Cornely A; Moussa A; Guigay J; Daoud J; Bourhis J;
Ann Oncol; 2018 Mar; 29(3):731-736. PubMed ID: 29236943
[TBL] [Abstract][Full Text] [Related]
27. Parallel genome-wide RNAi screens identify lymphocyte-specific protein tyrosine kinase (LCK) as a targetable vulnerability of cell proliferation and chemoresistance in nasopharyngeal carcinoma.
Liew K; Yu GQS; Wei Pua LJ; Wong LZ; Tham SY; Hii LW; Lim WM; OuYong BM; Looi CK; Mai CW; Fei-Lei Chung F; Tan LP; Ahmad M; Soo-Beng Khoo A; Leong CO
Cancer Lett; 2021 Apr; 504():81-90. PubMed ID: 33587980
[TBL] [Abstract][Full Text] [Related]
28.
Li Y; Yang X; Du X; Lei Y; He Q; Hong X; Tang X; Wen X; Zhang P; Sun Y; Zhang J; Wang Y; Ma J; Liu N
Clin Cancer Res; 2018 Dec; 24(24):6495-6508. PubMed ID: 30131385
[TBL] [Abstract][Full Text] [Related]
29. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
[TBL] [Abstract][Full Text] [Related]
31. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
[TBL] [Abstract][Full Text] [Related]
32. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
[TBL] [Abstract][Full Text] [Related]
33. MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma.
Bissey PA; Teng M; Law JH; Shi W; Bruce JP; Petit V; Tsao SW; Yip KW; Liu FF
BMC Cancer; 2020 Jun; 20(1):597. PubMed ID: 32586280
[TBL] [Abstract][Full Text] [Related]
34. [Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].
Bi T; Jin F; Wu W; Long J; Li Y; Gong X; Luo X; Li Z; He Q; Qu B
Zhonghua Zhong Liu Za Zhi; 2015 Sep; 37(9):676-81. PubMed ID: 26813432
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Kong L; Zhang YW; Hu CS; Guo Y
Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
[TBL] [Abstract][Full Text] [Related]
36. Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
Komatsu M; Tsukuda M; Matsuda H; Horiuchi C; Taguch T; Takahashi M; Nishimura G; Mori M; Niho T; Ishitoya J; Sakuma Y; Hirama M; Shiono O
Anticancer Res; 2012 Feb; 32(2):681-6. PubMed ID: 22287763
[TBL] [Abstract][Full Text] [Related]
37. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
38. Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma.
Wang F; Chuner J; Lei W; Fengqin Y; Zhimin Y; Quanquan S; Tongxin L; Zhenfu F; Yangming J
Medicine (Baltimore); 2020 Sep; 99(39):e22283. PubMed ID: 32991429
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of two different adjuvant chemotherapy regimens in combination with concurrent chemoradiotherapy in treating patients with advanced nasopharyngeal carcinoma: A protocol for randomized controlled trial.
Zhang LL; Cui J; Tan HF; Xiao Z; Pan LX
Medicine (Baltimore); 2021 May; 100(21):e25980. PubMed ID: 34032710
[TBL] [Abstract][Full Text] [Related]
40. Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma.
Gao M; Yuan T; Zhang F
J BUON; 2021; 26(1):116-123. PubMed ID: 33721441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
